ADE (chemotherapy)

ADE is a chemotherapy regimen most often used as an induction or consolidation regimen in acute myelogenous leukemia, especially in poor-risk patients or those refractory to the standard first-line induction with standard "7+3" regimen or who are relapsed after the standard chemotherapy.

ADE regimen consists of three drugs:

1. Ara-C (cytarabine) - an antimetabolite;
2. Daunorubicin - an anthracycline antibiotic that is able to intercalate DNA and thus disrupt the cell division cycle, preventing mitosis;
3. Etoposide - a topoisomerase inhibitor.